XENE RSI Chart
Last 7 days
-1.0%
Last 30 days
-6.6%
Last 90 days
-6.7%
Trailing 12 Months
4.7%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2022 | 22.8M | 21.2M | 13.2M | 9.4M |
2021 | 29.4M | 18.3M | 19.9M | 18.4M |
2020 | 13.9M | 27.3M | 30.3M | 32.2M |
2019 | 0 | 0 | 4.2M | 7.1M |
2017 | 0 | 0 | 1.5M | 1.1M |
2016 | 12.2M | 8.5M | 4.7M | 1.8M |
2015 | 27.4M | 26.1M | 17.2M | 15.6M |
2014 | 27.0M | 26.7M | 29.1M | 28.4M |
2013 | 17.6M | 20.8M | 24.1M | 27.4M |
2012 | 0 | 0 | 0 | 14.3M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 08, 2024 | garofalo elizabeth a. | sold | -95,583 | 45.69 | -2,092 | - |
Mar 08, 2024 | garofalo elizabeth a. | acquired | 64,960 | 18.56 | 3,500 | - |
Mar 08, 2024 | garofalo elizabeth a. | sold (taxes) | -64,993 | 46.16 | -1,408 | - |
Mar 07, 2024 | robin sherrington | sold (taxes) | -69,123 | 45.96 | -1,504 | evp, strategy & innovation |
Mar 07, 2024 | robin sherrington | acquired | 85,113 | 9.85 | 8,641 | evp, strategy & innovation |
Mar 07, 2024 | gannon steven | sold | -601,615 | 46.2781 | -13,000 | - |
Mar 07, 2024 | robin sherrington | sold | -330,290 | 46.2786 | -7,137 | evp, strategy & innovation |
Dec 29, 2023 | robin sherrington | sold | - | - | -8,398 | evp, strategy & innovation |
Dec 19, 2023 | azab mohammad | acquired | 42,552 | 9.85 | 4,320 | - |
Dec 14, 2023 | patou gary | sold | -311,898 | 41.05 | -7,598 | - |
Which funds bought or sold XENE recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Apr 18, 2024 | SJS Investment Consulting Inc. | unchanged | - | -15.00 | 216 | -% |
Apr 18, 2024 | Park Place Capital Corp | new | - | 775 | 775 | -% |
Apr 15, 2024 | Legato Capital Management LLC | added | 35.89 | 147,247 | 692,459 | 0.08% |
Apr 12, 2024 | AdvisorNet Financial, Inc | sold off | -100 | -92.00 | - | -% |
Apr 12, 2024 | DNB Asset Management AS | reduced | -0.1 | -384,506 | 5,435,060 | 0.03% |
Apr 11, 2024 | SANDERS MORRIS HARRIS LLC | unchanged | - | -101,480 | 925,575 | 0.17% |
Apr 11, 2024 | 17 CAPITAL PARTNERS, LLC | new | - | 391,693 | 391,693 | 0.29% |
Apr 10, 2024 | CVA Family Office, LLC | added | 60.61 | 762 | 2,282 | -% |
Apr 05, 2024 | GAMMA Investing LLC | added | 59.09 | 512 | 1,507 | -% |
Mar 22, 2024 | PNC FINANCIAL SERVICES GROUP, INC. | new | - | 91,198 | 91,198 | -% |
Unveiling Xenon Pharmaceuticals Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Xenon Pharmaceuticals Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 41.6B | 6.8B | -8.82 | 6.07 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 18.1B | 1.8B | -41.14 | 9.91 | ||||
BMRN | 17.2B | 2.4B | 102.64 | 7.11 | ||||
INCY | 11.6B | 3.7B | 19.44 | 3.14 | ||||
MID-CAP | ||||||||
APLS | 5.9B | 396.6M | -11.11 | 14.81 | ||||
BBIO | 4.5B | - | -6.85 | 60.35 | ||||
AXSM | 3.5B | 270.6M | -14.47 | 12.79 | ||||
ARWR | 2.9B | 240.7M | -9.93 | 12.18 | ||||
ACAD | 2.8B | 726.4M | -45.01 | 3.8 | ||||
SMALL-CAP | ||||||||
CPRX | 1.8B | 398.2M | 24.96 | 4.48 | ||||
NVAX | 580.8M | 983.7M | -1.07 | 0.59 | ||||
CRBP | 372.9M | 881.7K | -8.36 | 466.16 | ||||
INO | 237.4M | 4.9M | -1.76 | 48.79 | ||||
IBIO | 6.6M | 2.1M | -0.24 | 2.14 |
Xenon Pharmaceuticals Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2017Q4 | 2017Q3 | 2016Q4 | 2016Q3 | 2016Q2 | 2016Q1 | 2015Q4 |
Revenue | -100.0% | - | 132,000 | 536,000 | 8,766,000 | 3,737,000 | 8,124,000 | 2,218,000 | 4,358,000 | 5,150,000 | 6,554,000 | 13,384,000 | 7,078,000 | 3,329,000 | 3,500,000 | 16,000 | 264,000 | 376,000 | 413,000 | 413,000 | 601,000 | 3,227,000 |
Operating Expenses | 13.3% | 43,331,000 | 38,260,000 | 30,851,000 | 26,135,000 | 28,575,000 | 23,722,000 | 24,716,000 | 20,417,000 | 18,073,000 | 16,253,000 | 14,030,000 | 15,111,000 | 14,927,000 | 12,451,000 | - | - | - | - | - | - | - |
S&GA Expenses | -3.7% | 8,501,000 | 8,829,000 | 8,705,000 | 6,775,000 | 6,688,000 | 4,831,000 | 6,339,000 | 4,109,000 | 3,106,000 | 3,208,000 | 3,310,000 | 3,320,000 | 3,175,000 | 2,700,000 | - | - | - | - | - | - | - |
R&D Expenses | 18.3% | 34,830,000 | 29,431,000 | 22,146,000 | 19,360,000 | 21,887,000 | 18,891,000 | 18,377,000 | 16,308,000 | 14,967,000 | 13,045,000 | 10,720,000 | 11,791,000 | 11,752,000 | 9,751,000 | - | - | - | - | - | - | - |
EBITDA Margin | -53.2% | -13.10 | -8.56 | -4.29 | -3.59 | -4.23 | -3.27 | -3.19 | -1.23 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expenses | - | - | - | - | - | - | - | - | - | - | - | 154,000 | 330,000 | 348,000 | 363,000 | - | - | - | - | - | - | - |
Income Taxes | 294.0% | 1,139,000 | -587,000 | -40,000 | -394,000 | 484,000 | -205,000 | -217,000 | -68,000 | -14,000 | -203,000 | -39,000 | -1,000 | -36,000 | 5,000 | - | - | - | - | - | - | - |
Earnings Before Taxes | 3.9% | -36,256,000 | -37,737,000 | -31,198,000 | -20,064,000 | -25,080,000 | -15,650,000 | -22,326,000 | -15,832,000 | -12,337,000 | -9,058,000 | -214,000 | -7,485,000 | -11,412,000 | -8,866,000 | - | - | - | - | - | - | - |
EBT Margin | -53.3% | -13.28 | -8.66 | -4.35 | -3.64 | -4.28 | -3.33 | -3.26 | -1.27 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income | -0.7% | -37,395,000 | -37,150,000 | -31,158,000 | -19,670,000 | -25,564,000 | -15,445,000 | -22,109,000 | -15,764,000 | -12,323,000 | -8,855,000 | -175,000 | -7,484,000 | -11,376,000 | -8,871,000 | - | - | - | - | - | - | - |
Net Income Margin | -54.2% | -13.29 | -8.62 | -4.34 | -3.62 | -4.28 | -3.31 | -3.23 | -1.26 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Free Cashflow | -12.0% | -34,484,000 | -30,788,000 | -17,412,000 | -18,640,000 | -21,224,000 | -15,230,000 | -13,986,000 | -21,112,000 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | 43.8% | 965 | 671 | 685 | 720 | 754 | 776 | 807 | 558 | 572 | 264 | 275 | 291 | 189 | 199 | 211 | 237 | 148 | 99.00 | 106 | 115 | 122 |
Current Assets | 21.5% | 645 | 531 | 545 | 533 | 600 | 649 | 795 | 546 | 559 | 256 | 267 | 283 | 182 | 195 | 207 | 234 | 145 | 96.00 | 103 | 112 | 121 |
Cash Equivalents | 49.3% | 149 | 100 | 65.00 | 70.00 | 57.00 | 103 | 370 | 117 | 176 | 88.00 | 83.00 | 88.00 | 45.00 | 15.00 | 44.00 | 61.00 | 25.00 | 38.00 | 37.00 | 52.00 | 68.00 |
Net PPE | -5.7% | 10.00 | 10.00 | 10.00 | 8.00 | 7.00 | 5.00 | 5.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 3.00 | 2.00 | 2.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Liabilities | 6.9% | 37.00 | 35.00 | 38.00 | 33.00 | 33.00 | 23.00 | 22.00 | 16.00 | 22.00 | 15.00 | 18.00 | 14.00 | 18.00 | 17.00 | 21.00 | 49.00 | 56.00 | 24.00 | 23.00 | 22.00 | 19.00 |
Current Liabilities | 10.2% | 27.00 | 25.00 | 28.00 | 22.00 | 23.00 | 16.00 | 14.00 | 8.00 | 14.00 | 13.00 | 15.00 | 11.00 | 15.00 | 17.00 | 21.00 | 49.00 | 43.00 | 12.00 | 9.00 | 6.00 | 4.00 |
Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.00 | 12.00 | 13.00 | 15.00 | 15.00 |
LT Debt, Current | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 16.00 | 5.00 | 4.00 | 2.00 | - | - |
LT Debt, Non Current | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.00 | 12.00 | 13.00 | 15.00 | 15.00 |
Shareholder's Equity | 45.8% | 928 | 637 | 646 | 687 | 721 | 753 | 786 | 542 | 550 | 249 | 257 | 276 | 171 | 182 | 189 | 188 | 92.00 | 75.00 | 83.00 | 92.00 | 103 |
Retained Earnings | -7.2% | -665 | -620 | -571 | -524 | -482 | -445 | -408 | -377 | -357 | -331 | -316 | -294 | -278 | -266 | -257 | -257 | -249 | -238 | -229 | -219 | -207 |
Additional Paid-In Capital | 13.6% | 157 | 138 | 139 | 140 | 142 | 137 | 133 | 120 | 117 | 70.00 | 67.00 | 65.00 | 45.00 | 44.00 | 42.00 | 41.00 | 41.00 | 40.00 | 39.00 | 39.00 | 39.00 |
Shares Outstanding | 16.0% | 75.00 | 65.00 | 64.00 | 63.00 | 63.00 | 59.00 | 56.00 | 55.00 | 44.00 | 40.00 | 39.00 | 37.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | 2,443 | - | - | - | 1,881 | - | - | - | 751 | - | - | - | 383 | - | - | - | 228 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | 16.0% | -35,465 | -42,230 | -33,221 | -34,411 | -32,732 | -30,402 | -16,868 | -18,428 | -20,710 | -15,007 | -13,077 | -20,708 | -13,114 | -11,154 | -10,789 | -13,067 | 19,787 | -7,058 | -8,747 | -8,696 | -7,242 |
Share Based Compensation | 5.0% | 9,182 | 8,743 | 8,453 | 5,994 | 5,812 | 5,742 | 5,208 | 3,614 | 2,705 | 2,643 | 2,704 | 1,965 | 1,610 | 1,580 | 1,472 | 1,015 | 1,357 | 612 | 464 | 491 | 575 |
Cashflow From Investing | -599.1% | -239,726 | 48,032 | 27,902 | 46,622 | -14,335 | -234,097 | 1,317 | -48,888 | -215,433 | 15,575 | 8,192 | -55,104 | 43,199 | -18,032 | 10,934 | -52,925 | -60,318 | 7,740 | -6,628 | -7,003 | -12,556 |
Cashflow From Financing | - | 324,014 | - | - | - | 6.00 | 699 | 269,890 | 7,876 | 323,953 | 4,758 | 111 | 118,721 | 45.00 | - | -16,720 | 102,470 | 27,431 | 18.00 | 11.00 | 58.00 | 34.00 |
Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Income Statement [Abstract] | |||
Revenue (note 11) | $ 9,434 | $ 18,437 | |
Operating expenses: | |||
Research and development | $ 167,512 | 105,767 | 75,463 |
General and administrative | 46,542 | 32,810 | 21,967 |
Total operating expenses | 214,054 | 138,577 | 97,430 |
Loss from operations | (214,054) | (129,143) | (78,993) |
Other income (expense): | |||
Interest income | 27,620 | 8,713 | 466 |
Unrealized fair value gain (loss) on trading securities | 3,550 | (2,934) | (719) |
Foreign exchange gain (loss) | 199 | (1,891) | 358 |
Other income (expense) | 31,369 | 3,888 | 105 |
Loss before income taxes | (182,685) | (125,255) | (78,888) |
Income tax recovery (expense) (note 13) | 292 | (118) | 6 |
Net loss | (182,393) | (125,373) | (78,882) |
Net loss attributable to preferred shareholders | (437) | (1,795) | |
Net loss attributable to common shareholders | (182,393) | (124,936) | (77,087) |
Other comprehensive income (loss): | |||
Unrealized gain (loss) on available-for-sale securities (note 6) | 2,923 | (2,010) | |
Comprehensive loss | $ (179,470) | $ (127,383) | $ (78,882) |
Net loss per common share (note 4): | |||
Basic | $ (2.73) | $ (2.06) | $ (1.77) |
Diluted | $ (2.73) | $ (2.06) | $ (1.77) |
Weighted-average common shares outstanding (note 4): | |||
Basic | 66,889,005 | 60,542,142 | 43,627,452 |
Diluted | 66,889,005 | 60,542,142 | 43,627,452 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 148,643 | $ 57,242 |
Marketable securities (note 6) | 489,439 | 534,845 |
Accounts receivable | 874 | 986 |
Prepaid expenses and other current assets | 6,006 | 7,225 |
Total current assets | 644,962 | 600,298 |
Marketable securities, long-term (note 6) | 292,792 | 128,682 |
Operating lease right-of-use asset, net (note 8) | 9,193 | 10,406 |
Property, plant and equipment, net (note 7) | 9,653 | 6,500 |
Deferred tax assets (note 13) | 802 | 509 |
Prepaid expenses, long-term | 7,396 | 7,751 |
Total assets | 964,798 | 754,146 |
Current liabilities: | ||
Accounts payable and accrued expenses (note 9) | 25,974 | 22,214 |
Operating lease liability (note 8) | 1,299 | 488 |
Total current liabilities | 27,273 | 22,702 |
Operating lease liability, long-term (note 8) | 9,604 | 9,947 |
Total liabilities | 36,877 | 32,649 |
Shareholders’ equity: | ||
Common shares, without par value; unlimited shares authorized; issued and outstanding: 75,370,977 (December 31, 2022 - 62,587,701) (note 10) | 1,436,374 | 1,065,136 |
Additional paid-in capital | 156,764 | 142,108 |
Accumulated deficit | (665,140) | (482,747) |
Accumulated other comprehensive loss | (77) | (3,000) |
Total shareholders' equity | 927,921 | 721,497 |
Total liabilities and shareholders’ equity | 964,798 | 754,146 |
Commitments and contingencies (note 12) |